Status:
COMPLETED
South-seq: Deoxyribonucleic Acid (DNA) Sequencing for Newborn Nurseries in the South
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
University of Mississippi Medical Center
HudsonAlpha Institute for Biotechnology
Conditions:
Whole Genome Sequencing
Eligibility:
All Genders
Phase:
NA
Brief Summary
2,000 infants with signs suggestive of a genetic disorder being treated at a neonatal intensive care unit (NICU) in which African-American and rural populations are highly represented will be enrolled...
Detailed Description
Barriers to widespread and routine implementation of WGS-enabled clinical care exist at several levels. Surveys of clinicians indicate discomfort in their understanding of genomics and ability to comm...
Eligibility Criteria
Inclusion
- Parents/caregiver/guardian of a newborn (proband) who meets the inclusion criteria in Specific Aim 1
- Parent or caregiver/guardian is willing to participate and answer surveys
Exclusion
- Proband has secondary findings from WGS
- Parent or caregiver is not available to participate and answer surveys
- Parent or caregiver requires language interpreter services/translated materials
Key Trial Info
Start Date :
April 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
477 Patients enrolled
Trial Details
Trial ID
NCT03842995
Start Date
April 15 2019
End Date
December 31 2023
Last Update
December 13 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham/Children's of Alabama
Birmingham, Alabama, United States, 35294
2
Woman's Hospital
Baton Rouge, Louisiana, United States, 70895
3
University of Mississippi Medical Center
Jackson, Mississippi, United States, 39216